PROGRAMA DE PÓS-GRADUAÇÃO EM BIOQUÍMICA INSTITUTO DE QUÍMICA TECNOLOGIA ENZIMÁTICA APLICADA A FÁRMACOS RELATÓRIO DE PRÁTICAS:  PRODUÇÃO DE ASPARAGINASE POR…

11 Hemocyanins in the Immunotherapy of Superficial Bladder Cancer Sergio Arancibia1, Fabián Salazar1 and María Inés Becker1,2 1Fundación Ciencia y Tecnología para el…

1. Paolo A. Ascierto, MDUnit Melanoma, Cancer Immunotherapy and Innovative TherapyIstituto Nazionale Tumori – Fondazione “G. Pascale”, Napoli, ItalyThe Medical Need…

1. Understanding Renal Cell CarcinomaRonald M. Bukowski, MD Emeritus Staff, Consultant Cleveland Clinic Taussig Cancer Center Cleveland, Ohio 2. Overview 3. RCC Statistics…

1. Otranto 27 gennaio 2012MECCANISMI DI RESISTENZA AI FARMACINEL mRCC Michele Guida Dipartimento di Oncologia MedicaIstituto dei Tumori Bari 2. Drugs Resistance in mRCC1.…

1. Tyler J. Curiel, MD, MPH [email protected] of Medicine UT Health Science Center San Antonio, TX Reversing Immune Dysfunction in Cancer 2. Outline Introduction…

1. BTG 2013 FISH in Myeloma Dr Edmond S K Ma Department of Pathology Hong Kong Sanatorium & Hospital 2. BTG 2013 Agenda • Review HKS&H experience • CG abnormalities:…

1. Optimizing Chemotherapyfor Malignant GliomaState of the Art & Future Directions Roger Stupp, MD Multidisciplinary Oncology CenterUniversity Hospital (CHUV) Lausanne…

Slide 1 Slide 2 BR.21 Study Design *2:1 Randomization R Stratified by: Centre PS, 0/1 vs 2/3 Response to prior Rx (CR/PR:SD:PD) Prior regimens, (1 vs 2) Prior platinum, (Yes…

Slide 1HEREDITARY BREAST CANCER IN DEVELOPING COUNTRIES Richard G. Pestell, MD, PhD Kimmel Cancer Center Jefferson University Hospital Slide 2 Major Genetic Defects in Breast…